Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thalidomide + melphalan + bortezomib + stem cell transplant
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Stem Cell Therapies → Cell Therapies, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
This is a multi-agent combination regimen used primarily as a conditioning treatment before autologous stem cell transplantation in patients with multiple myeloma. The regimen includes: - **Thalidomide**: An immunomodulatory agent that inhibits angiogenesis, modulates the immune system, and has direct anti-myeloma effects. - **Melphalan**: An alkylating chemotherapy agent that crosslinks DNA and induces apoptosis in rapidly dividing cells. - **Bortezomib**: A proteasome inhibitor that disrupts protein degradation pathways within myeloma cells, leading to apoptosis. The combination is used to maximize cytoreduction prior to reinfusion of autologous hematopoietic stem cells. This approach aims to improve response rates and prolong remission in multiple myeloma patients eligible for high-dose therapy and transplantation[2][7]. The regimen may be followed by maintenance therapy with other agents depending on institutional protocols.
- Other names
- VMT (uncommon)MelVelThal (in some studies)
02
Targets
DNAPSMB5 (Proteasome subunit beta Type-5)CRBN (Cereblon)
Beyond the preview
Go deeper on thalidomide + melphalan + bortezomib + stem cell transplant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thalidomide + melphalan + bortezomib + stem cell transplant.